keyword
MENU ▼
Read by QxMD icon Read
search

Wellbutrin

keyword
https://www.readbyqxmd.com/read/27813651/a-systematic-review-of-the-use-of-bupropion-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
#1
Qin Xiang Ng
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatric disorders of childhood and adolescence. Stimulants are usually the first choice of drug; however, as many as 20% of patients do not respond to them. Stimulants may also worsen comorbid sleep, mood, and anxiety disorders, and they are associated with problems of misuse and diversion. Bupropion, a dopamine and norepinephrine reuptake inhibitor, is a promising nonstimulant alternative with reports of positive outcomes for ADHD management in both adolescent and adult populations...
November 4, 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27379819/utilizing-a-two-stage-design-to-investigate-the-safety-and-potential-efficacy-of-monthly-naltrexone-plus-once-daily-bupropion-as-a-treatment-for-methamphetamine-use-disorder
#2
Larissa J Mooney, Maureen P Hillhouse, Christie Thomas, Alfonso Ang, Gaurav Sharma, Garth Terry, Linda Chang, Robrina Walker, Madhukar Trivedi, David Croteau, Steven Sparenborg, Walter Ling
OBJECTIVES: This 2-stage open-label pilot study evaluated the safety and potential efficacy of naltrexone + bupropion as a pharmacotherapy for methamphetamine (MA) use disorder. METHODS: The study was conducted in 2 stages of recruitment across 3 sites; 20 participants were enrolled in stage 1 and 29 participants were enrolled in stage 2. Eight weeks of open-label pharmacotherapy with a combination of extended-release injectable naltrexone (XR-NTX; Vivitrol) plus extended-release oral bupropion (BRP; Wellbutrin XL) were provided with a smartphone-assisted medication adherence platform...
July 2016: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/27053517/drugs-to-treat-obesity-do-they-work
#3
REVIEW
Sarah Kim
Obesity is a disease that has historically eluded effective medical therapy. Prior to 2012, phentermine and orlistat were the only medications available to treat obesity in the USA, with phentermine approved only for short-term use. However, as of 2015, the repertoire of pharmacological agents available to treat obesity has greatly expanded to include four new drugs: lorcaserin, phentermine/topiramate extended release (ER), naltrexone ER/wellbutrin ER and liraglutide. Each has a unique mechanism of action and all are intended for long-term use...
July 2016: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/25087976/the-development-and-validation-of-a-turbulent-flow-liquid-chromatography-tandem-mass-spectrometric-method-for-the-simultaneous-quantification-of-citalopram-sertraline-bupropion-and-hydroxybupropion-in-serum
#4
Athena K Petrides, Joshua Moskowitz, Kamisha L Johnson-Davis, Paul J Jannetto, Loralie J Langman, William Clarke, Mark A Marzinke
OBJECTIVES: Depression is a rapidly growing issue in the United States. There are many drug classes that may be used to treat depression, including the selective serotonin-reuptake inhibitors (SSRIs) citalopram (Celexa®) and sertraline (Zoloft®), as well as the aminoketone bupropion (Wellbutrin®). However, therapeutic efficacy and treatment success is often variable, requiring changes in dosing regimens or drug selection. Methods for drug quantification can become important tools in the assessment of drug efficacy to optimize treatment regimens...
October 2014: Clinical Biochemistry
https://www.readbyqxmd.com/read/24533470/female-clitoral-priapism-an-over-the-counter-option-for-management
#5
Cecile A Unger, Mark D Walters
INTRODUCTION: Female priapism is a rare condition that is not commonly described in the literature. There are many treatment strategies for the management of priapism, including conservative and safe over-the-counter options. AIM: To describe a case of a woman who presented with clitoral priapism, who was managed conservatively with a simple over-the-counter treatment plan. METHODS: A 29-year-old gravida 0 para 0 presented to the emergency room with painful clitoral priapism lasting for 5 days...
September 2014: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/24201231/risks-and-benefits-of-bupropion-treatment-in-schizophrenia-a-systematic-review-of-the-current-literature
#6
REVIEW
Susanne Englisch, Katrin Morgen, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Bupropion inhibits the reuptake of norepinephrine and dopamine, which are involved in the pathogenesis of affective, cognitive, and psychomotor impairment in schizophrenia. Because of reports on bupropion-associated psychoses, it is reluctantly used in schizophrenic patients. Risks and benefits, however, have never been comprehensively reviewed. OBJECTIVE: The objectives of this study were to evaluate the efficacy of bupropion on depression, negative symptoms, cognition, and smoking habits in schizophrenia and to appraise safety aspects...
November 2013: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/24105221/wellbutrin-in-volunteer-studies-kinetics-and-dose-proportionality-of-bupropion-and-its-metabolites
#7
David H Schroeder, Richard J Fleck, Melvin L Hinton, John Y Chao, M Robert Blum
Wellbutrin (bupropion•HCl), a novel antidepressant in current clinical use, was evaluated in two pharmacokinetic, steady-state studies. Bupropion (B), and its 3 basic metabolites, hydroxy-t-butyl-bupropion (HB), erythro-hydro-bupropion (EB), and threo-hydro-bupropion (TB) plasma concentrations were determined by a high pressure liquid chromatographic method at several time points on the fourteenth day of each dosing regimen. Based on mean AUC and Cmax ratios from 22 male subjects, dose proportionality was observed between 100 and 150 mg t...
December 1994: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/23833432/assessment-of-potential-in-vitro-genotoxic-and-cytotoxic-effects-of-bupropion-hydrochloride-wellbutrin-in-human-peripheral-lymphocytes-and-human-cortical-neuron
#8
Saurabh Kumar Bhattacharya, Lokendra Singh Nathawat, Priyankka Damani, Arpan Kumar Choksi, Arpita Banik, Kriti Sinha, Aditi Sarkar Bhattacharya
INTRODUCTION: Wellbutrin (bupropion hydrochloride; WB), an anti-depressant of the aminoketone class is new highly selective norepinephrine and dopamine reuptake inhibitor; it is effective in the treatment of patients with major depression. MATERIALS AND METHODS: To investigate the in vitro effects of WB in human cultured peripheral blood lymphocytes and human cortical neural (HCN2) cell lines, micronucleus, sister chromatid exchange analysis, cellular viability, and comet assays were employed...
January 2013: Toxicology International
https://www.readbyqxmd.com/read/23694796/how-can-a-methadone-and-an-opiate-positive-immunoassay-result-be-reconciled-in-a-patient-prescribed-only-oxycontin-and-wellbutrin
#9
Jude M Abadie
Appropriate management of patients in pain clinics can be complex and sometimes confusing because providers must correctly interpret multiple sources of patient information. The correct interpretation of laboratory results is essential to guide subsequent patient treatment and management; however, laboratory and clinical pictures can appear to be conflicting in cases of substance abuse. Incorrect interpretation of laboratory results can multiply negative impacts on clinical outcomes and may lead to patient harm or death...
2013: Annals of Clinical and Laboratory Science
https://www.readbyqxmd.com/read/23238783/the-influence-of-sex-ethnicity-and-cyp2b6-genotype-on-bupropion-metabolism-as-an-index-of-hepatic-cyp2b6-activity-in-humans
#10
COMPARATIVE STUDY
Katarina Ilic, Roy L Hawke, Ranjit K Thirumaran, Erin G Schuetz, J Heyward Hull, Angela D M Kashuba, Paul W Stewart, Celeste M Lindley, Mei-Ling Chen
The effects of sex, ethnicity, and genetic polymorphism on hepatic CYP2B6 (cytochrome P450 2B6) expression and activity were previously demonstrated in vitro. Race/ethnic differences in CYP2B6 genotype and phenotype were observed only in women. To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate. A fixed 150-mg oral sustained-release dose of bupropion was administered to 100 healthy volunteers comprising four sex/ethnicity cohorts (n = 25 each): Caucasian men and Caucasian, African American, and Hispanic women...
March 2013: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/23216549/withdrawal-of-generic-budeprion-for-nonbioequivalence
#11
Janet Woodcock, Mansoor Khan, Lawrence X Yu
The Food and Drug Administration (FDA) has completed a head-to-head bioequivalence study of single doses of the generic drug Budeprion XL 300 mg (extended-release bupropion hydrochloride, manufactured by Impax Laboratories and distributed by Teva Pharmaceuticals) and the brand-name drug Wellbutrin..
December 27, 2012: New England Journal of Medicine
https://www.readbyqxmd.com/read/22468662/wellbutrin%C3%A2-misuse-and-abuse-by-incarcerated-individuals
#12
DeAnne Phillips
Misuse and abuse of prescription medications is increasing across both socioeconomic and age parameters. This article includes a review of the uses of Wellbutrin®, and its current misuse/abuse within the correctional setting. It includes a discussion regarding the pharmacodynamics involved in substance abuse. A review of current literature includes both academic research and public forums regarding this topic. It also discusses the role of dopamine in both Wellbutrin® and substance use. The author identifies the lack of current research regarding this topic and poses ethical questions for the provider...
February 2012: Journal of Addictions Nursing
https://www.readbyqxmd.com/read/22119468/-%C3%A2-2-n-tert-butylamino-3-125-i-iodo-4-azidopropiophenone-a-dopamine-transporter-and-nicotinic-acetylcholine-receptor-photoaffinity-ligand-based-on-bupropion-wellbutrin-zyban
#13
David J Lapinsky, Shaili Aggarwal, Tammy L Nolan, Christopher K Surratt, John R Lever, Rejwi Acharya, Roxanne A Vaughan, Akash Pandhare, Michael P Blanton
Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4'-position of the aromatic ring. Analog (±)-3 (SADU-3-72) demonstrated modest DAT and α4β2 nAChR affinity. A radioiodinated version was shown to bind covalently to hDAT expressed in cultured cells and affinity-purified, lipid-reincorporated human α4β2 neuronal nAChRs...
January 1, 2012: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/21511205/repetitive-transcranial-magnetic-stimulation-for-tinnitus-treatment-no-enhancement-by-the-dopamine-and-noradrenaline-reuptake-inhibitor-bupropion
#14
Tobias Kleinjung, Thomas Steffens, Michael Landgrebe, Veronika Vielsmeier, Elmar Frank, Julia Burger, Juergen Strutz, Göran Hajak, Berthold Langguth
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) of the temporal cortex has shown beneficial effects in patients with chronic tinnitus. Recent preclinical data in healthy controls suggest that the effects of low-frequency rTMS can be enhanced by dopaminergic drugs. OBJECTIVE: We investigated whether application of the dopamine reuptake inhibitor bupropion increases the clinical effects of low-frequency rTMS over the auditory cortex in tinnitus patients...
April 2011: Brain Stimulation
https://www.readbyqxmd.com/read/21397882/using-time-series-intervention-analysis-to-understand-u-s-medicaid-expenditures-on-antidepressant-agents
#15
Yann Ferrand, Christina M L Kelton, Jeff J Guo, Martin S Levy, Yan Yu
BACKGROUND: Medicaid programs' spending on antidepressants increased from $159 million in 1991 to $2 billion in 2005. The National Institute for Health Care Management attributed this expenditure growth to increases in drug utilization, entry of newer higher-priced antidepressants, and greater prescription drug insurance coverage. Rising enrollment in Medicaid has also contributed to this expenditure growth. OBJECTIVES: This research examines the impact of specific events, including branded-drug and generic entry, a black box warning, direct-to-consumer advertising (DTCA), and new indication approval, on Medicaid spending on antidepressants...
March 2011: Research in Social & Administrative Pharmacy: RSAP
https://www.readbyqxmd.com/read/20684153/a-case-of-bupropion-induced-stevens-johnson-syndrome-with-acute-psoriatic-exacerbation
#16
Jamie Surovik, Catherine Riddel, Susan Y Chon
Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation (Zyban, GlaxoSmithKline, Research Triangle Park, NC). It has been reported to have some common dermatologic side effects, such as pruritus, urticaria and serum-sickness like reaction. The authors report a case of bupropion-induced Stevens-Johnson syndrome (SJS) with a concomitant acute psoriatic exacerbation in a 56-year-old woman, who began taking bupropion for treatment of depression...
August 2010: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/20436760/use-of-antidepressants-expansion-beyond-depression-and-anxiety
#17
Elisa F Cascade, Amir H Kalali, Michael E Thase
We investigated antidepressant prescriptions and reasons for use. According to our data, the top 10 molecules represent approximately 95% of total antidepressant prescriptions for both primary care physicians (PCPs) and psychiatrists. The primary difference between PCPs and psychiatrists was the increased use of buproprion and tricyclics/tetracyclics by psychiatrists. The selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants such as venlafaxine (Effexor) and buproprion (Wellbutrin) are used to treat depression, anxiety, and bipolar disorders...
December 2007: Psychiatry
https://www.readbyqxmd.com/read/20066523/investigation-into-the-dissolution-rate-increase-on-storage-of-wellbutrin-sr-100-mg-tablets
#18
Mickey L Wells, Sandra O Williams, Ronald A Sanftleben, Samuel B Balik, Barry A Evans
The Food and Drug Administration (FDA) approved the New Drug Application for Wellbutrin sustained release (SR) 100 mg tablets on October 4, 1996. However, by 1998, the FDA expressed concern about the stability of this drug product based on an increase in the dissolution profile on storage. Data submitted in the annual report showed that this drug product could not meet the expiry of 18 months at the International Committee on Harmonization storage condition of 25 degrees C/60% relative humidity. The FDA mandated a 12-month expiry and GlaxoWellcome tightened this further by instituting an expiry of 9 months...
March 2010: AAPS PharmSciTech
https://www.readbyqxmd.com/read/19238934/-psychiatry
#19
Nicola Gervasoni, Christian Bryois, Rémy Barbe, Gilles Bertschy
In 2008 there is no major breakthrough in the field of psychopharmacology. Paliperidone, (Invega), or 9-hydroxyrisperidone, the main hydroxylated metabolite of risperidone, is now available in Switzerland. It has the same pharmacodynamic profile and a different pharmacokinetic profile, linked to an extended release preparation. Bupropion, an antidepressant with noradrenergic and dopaminergic activity, is now accepted on the Swiss market for the treatment of depression under the name of Wellbutrin. Until now, its indication was limited to tobacco withdrawal (under the name of Zyban)...
January 14, 2009: Revue Médicale Suisse
https://www.readbyqxmd.com/read/19193596/bupropion-as-a-possible-treatment-option-for-restless-legs-syndrome
#20
Jennifer J Lee, Joseph Erdos, Meghan F Wilkosz, Renee LaPlante, Brenda Wagoner
OBJECTIVE: To describe a case of restless legs syndrome (RLS) successfully managed with bupropion. CASE SUMMARY: A 45-year-old female presented to a Veterans Affairs primary care clinic with a history of chronic insomnia. Her complicated history of treatment failure to sedative-hypnotic agents, continued sleep disturbances, and complaints of intolerable leg sensations fostered collaboration between a psychiatrist and pharmacist to identify effective treatment. Further review of her medical history and subjective complaints led to a diagnosis of RLS...
February 2009: Annals of Pharmacotherapy
keyword
keyword
11912
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"